New cocktail aims to wake up sleeping HIV
NCT ID NCT07635992
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether combining two drugs—ibalizumab and chidamide—can safely reduce the hidden HIV reservoir in people living with HIV. The study will enroll up to 29 adults on stable antiretroviral therapy. Researchers will monitor side effects and measure changes in HIV DNA levels in blood cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibalizumab (monoclonal antibody) and chidamide (histone deacetylase inhibitor)
What this could lead to
If successful, this could point toward a strategy to reduce hidden HIV reservoirs, potentially allowing people with HIV to manage the virus without lifelong daily medication.
What could go wrong
This is a very early Phase 1 trial with only 18-29 participants. It primarily tests safety, not effectiveness. The combination may cause side effects or fail to shrink the viral reservoir significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.